{
  "author": {
    "name": "Robert Langreth",
    "webUrl": "/author/profile/robert-langreth/",
    "description": "",
    "imageLarge": "https://secure.gravatar.com/avatar/f16d6fc2845f417ea0e93a3f2b6cd37d?s=136&d=mm&r=g",
    "estimate": 56,
    "social": [],
    "articles": [
      {
        "uri": "/2023/07/07/fda-approves-first-alzheimers-drug-to-slow-the-diseases-progression/",
        "title": "FDA approves first Alzheimer's drug to slow the disease's progression",
        "byline": "Robert Langreth",
        "kicker": "News",
        "prettyDate": "July 07, 2023",
        "timeToRead": "4 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/11/365-5-amyloid-151645089-616x372-TS.jpg",
          "width": "616",
          "height": "372"
        },
        "authors": [
          {
            "webUrl": "/author/profile/robert-langreth/",
            "name": "Robert Langreth"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "Leqembi - among the most potent of a new generation of antibodies that help clear a toxic protein that slowly builds up in the brains of Alzheimer's patients - is expected to lead to far greater coverage by insurers and Medicare.",
        "body": null
      },
      {
        "uri": "/2023/06/27/the-race-is-on-some-drugmakers-falling-behind-in-developing-new-weight-loss-pills/",
        "title": "The race is on: Some drugmakers falling behind in developing new weight loss pills",
        "byline": "Emma Court, Robert Langreth and Matthew Griffin",
        "kicker": "Update",
        "prettyDate": "June 27, 2023",
        "timeToRead": "5 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2023/06/Medical-Research-Scientists-Article-202306270840.jpg",
          "width": "620",
          "height": "372"
        },
        "authors": [
          {
            "webUrl": "/author/profile/emma-court-robert-langreth/",
            "name": "Emma Court, Robert Langreth"
          },
          {
            "webUrl": "/author/profile/matthew-griffin/",
            "name": "Matthew Griffin"
          }
        ],
        "kickerNode": [
          {
            "uri": "/update/",
            "sectionName": "Update"
          }
        ],
        "summary": "Drugmakers have been rushing to develop obesity pills (to rival obesity shots like Wegovy), angling for a piece of a market that some estimate will one day be worth as much as $100 billion.",
        "body": null
      },
      {
        "uri": "/2023/05/19/sareptas-gene-therapy-gets-accelerated-approval-are-fda-fast-tracked-drugs-safe/",
        "title": "Sarepta's gene therapy gets FDA accelerated approval: Are fast-tracked drugs safe?",
        "byline": "Robert Langreth, Fiona Rutherford, Immanual John Milton and Madeline Campbell",
        "kicker": "Market Insights",
        "prettyDate": "May 19, 2023",
        "timeToRead": "9 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2020/09/Pharmaceutical-Lab-Article-202009151515.jpg",
          "width": "0",
          "height": "0"
        },
        "authors": [
          {
            "webUrl": "/author/profile/robert-langreth-fiona-rutherford-immanual-john-milton/",
            "name": "Robert Langreth, Fiona Rutherford, Immanual John Milton"
          },
          {
            "webUrl": "/author/profile/madeline-campbell/",
            "name": "Madeline Campbell"
          }
        ],
        "kickerNode": [
          {
            "uri": "/market-insights/",
            "sectionName": "Market Insights"
          }
        ],
        "summary": "The recommendation is a huge win for the pharmaceutical company, likely paving the way for the company's first-of-its-kind gene therapy for treat Duchenne muscular dystrophy, a deadly disease.",
        "body": null
      },
      {
        "uri": "/2022/06/08/new-drug-prices-soar-to-180000-a-year-on-20-annual-inflation/",
        "title": "New drug prices soar to $180,000 a year on 20% annual inflation",
        "byline": "Robert Langreth",
        "kicker": "",
        "prettyDate": "June 08, 2022",
        "timeToRead": "2 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2022/06/Pharmaceutical-drug-Cagkan-Sayin-at-shutterstock.jpg",
          "width": "617",
          "height": "409"
        },
        "authors": [
          {
            "webUrl": "/author/profile/robert-langreth/",
            "name": "Robert Langreth"
          }
        ],
        "kickerNode": [],
        "summary": "Attention has focused on price hikes for existing prescription drugs, but soaring launch prices also contribute to rising costs.",
        "body": null
      },
      {
        "uri": "/2020/10/30/covid-continues-to-put-a-damper-on-health-pharma-industries/",
        "title": "COVID continues to put a damper on health, pharma industries",
        "byline": "Emma Court, Robert Langreth, John Tozzi and Riley Griffin",
        "kicker": "Market Insights",
        "prettyDate": "October 30, 2020",
        "timeToRead": "6 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2020/10/covid-19-coronavirus-economy-money-chart-stocks.jpg",
          "width": "0",
          "height": "0"
        },
        "authors": [
          {
            "webUrl": "/author/profile/emma-court-robert-langreth-john-tozzi/",
            "name": "Emma Court, Robert Langreth, John Tozzi"
          },
          {
            "webUrl": "/author/profile/riley-griffin/",
            "name": "Riley Griffin"
          }
        ],
        "kickerNode": [
          {
            "uri": "/market-insights/",
            "sectionName": "Market Insights"
          }
        ],
        "summary": "For drugmakers, the pandemic has squeezed demand for everything from childhood vaccines to smoking-cessation drugs.",
        "body": null
      },
      {
        "uri": "/2020/06/29/cost-for-gileads-remdesivir-treatment-for-covid-19-2340/",
        "title": "Cost for Gilead's remdesivir treatment for COVID-19? $2,340",
        "byline": "Robert Langreth",
        "kicker": "News",
        "prettyDate": "June 29, 2020",
        "timeToRead": "4 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/04/DrugVials.jpg",
          "width": "600",
          "height": "400"
        },
        "authors": [
          {
            "webUrl": "/author/profile/robert-langreth/",
            "name": "Robert Langreth"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "That's the government price--the list price for private insurers will be $3,120 for a five-day course.",
        "body": null
      },
      {
        "uri": "/2019/06/06/health-care-data-hacks-drawing-attention-of-congress/",
        "title": "Health care data hacks drawing attention of Congress",
        "byline": "Robert Langreth",
        "kicker": "News",
        "prettyDate": "June 06, 2019",
        "timeToRead": "3 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2019/01/PrivacyConcept.jpg",
          "width": "591",
          "height": "396"
        },
        "authors": [
          {
            "webUrl": "/author/profile/robert-langreth/",
            "name": "Robert Langreth"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "Senators wrote to Quest Diagnostics asking about its recent breach, one of a growing number of such incidents in the health care sector.",
        "body": null
      },
      {
        "uri": "/2019/06/03/11-9-million-patient-records-exposed-in-quest-data-breach/",
        "title": "11.9 million patient records exposed in Quest data breach",
        "byline": "Robert Langreth",
        "kicker": "News",
        "prettyDate": "June 03, 2019",
        "timeToRead": "2 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/03/08Hack.jpg",
          "width": "600",
          "height": "338"
        },
        "authors": [
          {
            "webUrl": "/author/profile/robert-langreth/",
            "name": "Robert Langreth"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "Quest, which operates medical testing centers around the U.S., is working with law enforcement and UnitedHealth on the effects of the breach. ",
        "body": null
      },
      {
        "uri": "/2019/04/10/senators-call-for-investigation-into-pbms-spread-pricing/",
        "title": "Senators call for investigation into PBM's spread pricing",
        "byline": "Anna Edney and Robert Langreth",
        "kicker": "News",
        "prettyDate": "April 10, 2019",
        "timeToRead": "3 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/03/DrugPrices.jpg",
          "width": "600",
          "height": "400"
        },
        "authors": [
          {
            "webUrl": "/author/profile/anna-edney/",
            "name": "Anna Edney"
          },
          {
            "webUrl": "/author/profile/robert-langreth/",
            "name": "Robert Langreth"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "The scrutiny is part of a wider inquiry by lawmakers into U.S. drug costs that has involved several Senate hearings.",
        "body": null
      },
      {
        "uri": "/2019/04/05/blink-health-and-the-rocky-journey-to-reform/",
        "title": "Blink Health's rocky journey to reform drug prices",
        "byline": "Robert Langreth",
        "kicker": "Profile",
        "prettyDate": "April 05, 2019",
        "timeToRead": "18 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/12/DrugPriceFixing.jpg",
          "width": "616",
          "height": "372"
        },
        "authors": [
          {
            "webUrl": "/author/profile/robert-langreth/",
            "name": "Robert Langreth"
          }
        ],
        "kickerNode": [
          {
            "uri": "/profile/",
            "sectionName": "Profile"
          }
        ],
        "summary": "Blink's vision was clouded by management turmoil, frequent turnover and underestimating resistance to drug reform.",
        "body": null
      }
    ]
  }
}